Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service

Codiak Presents First Preclinical Data for exoASO, Engineered Exosomes Designed to Reprogram Tumor-Associated Macrophages


Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced the first preclinical data for its engExtm Platform program, exoASOtm. These data, which were presented at the American Association for Cancer Research's Special Conference on Tumor Immunology and Immunotherapy, demonstrate the potential of engineered exosomes incorporating an antisense oligonucleotide (ASO) to selectively reprogram tumor-associated macrophages and generate potent anti-tumor activity.

"We continue to expand the therapeutic potential of engEx engineered exosomes and build our pipeline of novel biologics designed to target pathways that have been historically difficult to effectively or safely drug," said Douglas E. Williams, Ph.D., President and Chief Executive Officer of Codiak. "These data show us the utility of exoASO in both selectively targeting classically undruggable transcription factors and successfully reprogramming immunosuppressive macrophages, representing a potentially groundbreaking approach."

Highly immunosuppressive macrophages (M2 phenotype) are immune cells that are potent drivers of tumor growth by creating an immunesuppressive environment in the tumor. Utilizing its proprietary engEx Platform, Codiak developed engineered exosomes exogenously loaded with an ASO as part of its exoASO program. exoASO is designed to selectively deliver ASOs to M2 macrophages, targeting and decreasing the expression of the key immunosuppressive transcription factors, STAT6 and C/EBP?.

Key conclusions from in vitro and in vivo preclinical studies demonstrate that exoASO effectively reprogrammed M2 macrophages to a pro-inflammatory M1 phenotype, promoting targeted anti-tumor activity. In vitro, exoASO was preferentially taken up by M2 macrophages to a significantly greater extent than free ASO, resulting in greater knockdown of STAT6 and C/EBP? mRNA. Subsequent gene expression analysis and cytokine assays showed an up to 40-fold increase in TNF? and an up to 29-fold decrease in IL-10 associated with exoASO treatment, consistent with repolarization from immunosuppressive M2 macrophages to immune stimulatory M1 macrophages. In in vivo studies using a PD1-refractory mouse tumor model, both exoASO-STAT6 and exoASO-C/EBP? showed significant anti-tumor growth inhibition as monotherapies, resulting in 50 percent and 60 percent complete responses, respectively, compared to no complete responses with free ASO. mRNA analysis of tumor samples examining expression of M2 and M1 cytokines was consistent with reprogrammed macrophages from the M2 to M1 phenotype.

Data from the poster titled "Reprogramming of tumor-associated M2 macrophages with antisense oligonucleotides-loaded exosomes results in potent single-agent antitumor activity" (A50) is available for download on the Codiak website.

About engExtm Platform

The engEx Platform is Codiak's proprietary exosome therapeutic engine for engineering and manufacturing novel exosome product candidates designed to target multiple pathways throughout the body. Using this platform, Codiak can design exosomes with precisely engineered properties, incorporate various types of biologically active molecules and direct them to specific cell types and tissues. These exosomes engage by cellular uptake, membrane-to-membrane interaction or a combination of both, and are designed to change the biological functioning of the recipient cells in order to produce the intended therapeutic effect. Codiak is building a broad pipeline of engEx product candidates that may have a transformative impact on the treatment of many diseases.

About Codiak BioSciences

Codiak BioSciences is harnessing exosomes?natural intercellular messengers?to develop a new class of biologic medicines, exosome therapeutics. Utilizing our proprietary and versatile exosome engineering and manufacturing platform (engExtm Platform), Codiak is developing exosomes with precisely engineered properties to engage pathways and deliver potent therapeutics to specific cell targets. We are building a broad pipeline of therapeutic candidates that may have a transformative impact on the treatment of many diseases, including in the areas of oncology, immune-based diseases, fibrotic disorders, neurological disorders and rare diseases. For more information, visit http://www.codiakbio.com.


These press releases may also interest you

at 15:00
Missional Marketing, an agency that has spent the last 12 years working with hundreds of churches (ranging from just a few attendees to the largest mega-churches) has a bird's eye view on how these organizations have been handling COVID-19. With...

at 14:39
The University of Mississippi Medical Center and the Mississippi State Department of Health on Tuesday will open two mobile COVID-19 sample collection sites for one day only....

at 14:30
WOW! Internet, Cable & Phone , a leading broadband provider, today issued the following statement: WOW! CEO Teresa Elder, was...

at 12:53
The number of individuals worldwide watching American Jewish Committee (AJC) Advocacy Anywhere programming is growing as the Coronavirus pandemic compels many across the United States and in countries around the world to stay in their homes. The new...

at 12:00
Consistent with her commitment to children's health and education, Bharti Shah, CEO, CTIS, Inc. is joining hands with Children's National Hospital to build the first of its kind pediatric COVID-19 test site in the country for the District of...

at 10:00
Today, in the context of the COVID-19 virus pandemic, many employees have switched to remote work. Because of this, software that they are used to working with at the office is often not available to them. Users often need to batch convert files from...



News published on 18 november 2019 at 16:10 and distributed by: